Krebs Biochemicals & Industries

₹57.50As of Sun 8 Nov 2026, 12:00 UTC

NSE:KREBSBIOHealthcare

Country India

PE (Fwd) —

TSR 10Y CAGR (5.14%)

Div yield —

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.90

PE TTM —

TSR TTM (16.71%)

Mkt cap ₹1.252B

ROIC —

SE Grade™

—

Value

Quality

Moat

—

1Y Price

Reference

₹64

11.96%

(96.68%)

Price above Reference Value

FY23

FY24

FY25

FY26

Earnings per share₹

(11.45)

(9.15)

(12.49)

(7.85)

44.55%

20.10%

(36.55%)

37.14%

Revenue₹M

521.3

504.2

433.1

237.3

(12.68%)

(3.29%)

(14.10%)

(45.21%)

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

237.3

Revenue₹M

—

597.0

521.3

504.2

433.1

237.3

212.1

(20.60%)

(45.21)

Revenue growth%

—

(12.68)

(3.29)

(14.10)

(45.21)

(10.62)

(13.39)

—

94.43

Gross margin%

—

26.10

46.84

81.36

76.84

94.43

95.08

76.84

(42.00)

Operating margin%

—

(66.15)

(41.90)

(30.14)

(49.16)

(42.00)

(41.24)

(42.00)

(71.35)

Net margin%

—

(74.58)

(47.36)

(39.13)

(62.20)

(71.35)

(70.50)

(62.20)

—

P/E ratio (avg)x

—

EV/EBITx

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

(7.85)

EPS₹

—

(20.65)

(11.45)

(9.15)

(12.49)

(7.85)

(6.94)

—

37.14

EPS growth%

—

44.55

20.10

(36.55)

37.14

11.68

28.62

—

Bookvalue per sh₹

—

FCF per share₹

—

Dividend per sh₹

—

Div yield (avg)%

—

Payout ratio%

—

21.56

Shares (diluted)M

—

21.56

◌21.56

—

Buyback yield%

—

◌—

—

D/E ratiox

—

1.240

Enterprise value₹B

—

3.436

2.400

1.561

1.982

1.614

1.240

(17.21%)

—

LT debt₹M

—

Peers (US$12.83M)

Cap (US$)

Bal Pharma Limited

13.93M

18.09x

Balaxi Pharmaceuticals…

12.93M

49.20x

Alpa Laboratories…

12.08M

25.54x

UniPharma Co., Ltd.

12.87M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

(1.407)

(3.604)

Own earn%

—

Sh yield%

—

Owners

Insiders/Inst%

26.71

—

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

0/5

Revenue growth years

0/4

EPS growth years

3/4

Dividend streakyrs

Op margin range%

−66–−30

$1 testx

—

Incr. ROIC%

—

Krebs Biochemicals & Industries Limited engages in the manufacture of active pharmaceutical ingredients in India. It offers androstenedione for steroid intermediate indications, as well as lovastatin and simvastatin for anti-cholesterol applications.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹237.3M

(20.60%)

1.00×

Cost of revenue

₹13.21M

(58.40%)

0.08×

Operating expenses

₹323.8M

(12.44%)

1.48×

Revenue by region

No breakdown available

Reinvestment returns

No breakdown available